Precigen Reports First Quarter 2021 Financial Results
- Company on track to achieve stated 2021 milestones -
- Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy -
- Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) -
- Upcoming presentation at FOCIS Virtual Annual Meeting to provide clinical progress for AG019 ActoBiotics™ in Type 1 diabetes (T1D) -
News provided by
Share this article
Share this article
GERMANTOWN, Md., May 10, 2021 /PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results.
Why even with vaccines, COVID-19 will always be with us
Jason Gale
View Comments
The road to eliminating COVID-19 is long and paved with uncertainty. Many countries are counting on vaccines to build sufficient immunity in their populations so that SARS-CoV-2 isn t able to find susceptible people to infect, causing transmission of the coronavirus to slow and eventually stop. But even with the rollout of highly effective vaccines, immunization coverage may not reach that level the so-called herd immunity threshold anytime soon. For one thing, it s not known what level of immunity is required. There s also the threat of emerging coronavirus variants that may weaken the effectiveness of immunizations.
Washington: The road to eliminating COVID-19 is long and paved with uncertainty. Many countries are counting on vaccines to build sufficient immunity in their populations so that SARS-CoV-2 isn’t able to find susceptible people to infect, causing transmission of the coronavirus to slow and eventually stop.
But even with the rollout of highly effective vaccines, immunisation coverage may not reach that level - the so-called herd immunity threshold - anytime soon. For one thing, it’s not known what level of immunity is required. There’s also the threat of emerging coronavirus variants that may weaken the effectiveness of immunisations.
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing
- Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration resulting in a $15 million milestone payment earned in April 2021
- EMD Serono began a Phase 1 study for the bispecific MUC1-EGFR ADC, M1231, during the first quarter of 2021
- Financial position remains strong with cash, cash equivalents and marketable securities of $294.9 million as of March 31, 2021 and projected runway into the second half of 2023
Spotlight on Georg Luebeck
Georg Luebeck, Computational Biologist and Molecular Clockmaker
As a trained physicist, he could have ended up designing rockets for Boeing, shaping young minds at a university, or making any number of other scientific contributions.
Instead, “by a stroke of luck,” Dr. Georg Luebeck wound up at Fred Hutchinson Cancer Research Center, where for the last 30-plus years, his mathematical models of biological processes like cancer initiation and growth have helped everyone from uranium miners at risk for lung cancer to astronauts facing the effects of galactic cosmic radiation.
“It’s coming up to 32 years. Or is it 33?” Luebeck said of his time at the Hutch. “So much of the research and the methods and the technologies have changed. We didn’t have the genome then. We didn’t understand so many things. Now we have affordable, whole-genome sequencing and array technologies to interrogate genomes down to the single-cell level.”